Yaodong Zhou1, Kai Li, Shan Zheng, Lian Chen. 1. Department of Surgery, Children's Hospital, Medical Center of Fudan University, 399 Wang Yuan Road, Shanghai, 201102, People's Republic of China.
Abstract
PURPOSE: The purpose of the study is to review the clinical features, treatments, and outcomes of neonatal neuroblastoma (NB). METHODS: A retrospective analysis was performed on 42 patients with NB between January 1994 and December 2011. RESULTS: MYCN amplification was detected in nine tumor samples. The ratio of unfavorable histology to favorable histology was 1:2 in NB patients. The 5-year overall survival (OS) of NB patients was 85.7 %. The 5-year OS in patients in the operation group was 83.3 %, chemotherapy group was 83.3 %, and the "wait-and-see" group was 100 % (P = 0.04). Overall, the prognosis was favorable, except in patients with elevated MYCN amplification or vanillylmandelic acid. CONCLUSIONS: NB patients were more sensitive and vulnerable to chemotherapy and operation. The "wait-and-see" strategy should be highlighted in the treatment of NB.
PURPOSE: The purpose of the study is to review the clinical features, treatments, and outcomes of neonatal neuroblastoma (NB). METHODS: A retrospective analysis was performed on 42 patients with NB between January 1994 and December 2011. RESULTS:MYCN amplification was detected in nine tumor samples. The ratio of unfavorable histology to favorable histology was 1:2 in NB patients. The 5-year overall survival (OS) of NB patients was 85.7 %. The 5-year OS in patients in the operation group was 83.3 %, chemotherapy group was 83.3 %, and the "wait-and-see" group was 100 % (P = 0.04). Overall, the prognosis was favorable, except in patients with elevated MYCN amplification or vanillylmandelic acid. CONCLUSIONS: NB patients were more sensitive and vulnerable to chemotherapy and operation. The "wait-and-see" strategy should be highlighted in the treatment of NB.
Authors: H Xue; J R Horwitz; M B Smith; K P Lally; C T Black; A Cangir; H Takahashi; R J Andrassy Journal: J Pediatr Surg Date: 1995-04 Impact factor: 2.545
Authors: H M Katzenstein; L C Bowman; G M Brodeur; P S Thorner; V V Joshi; E I Smith; A T Look; S T Rowe; M B Nash; T Holbrook; C Alvarado; P V Rao; R P Castleberry; S L Cohn Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Anna Rita Gigliotti; Andrea Di Cataldo; Stefania Sorrentino; Stefano Parodi; Antonino Rizzo; Piero Buffa; Claudio Granata; Angela Rita Sementa; Anna Maria Fagnani; Massimo Provenzi; Arcangelo Prete; Carmelita D'Ippolito; Anna Clerico; Aurora Castellano; Gian Paolo Tonini; Massimo Conte; Alberto Garaventa; Bruno De Bernardi Journal: Eur J Cancer Date: 2009-09-18 Impact factor: 9.162
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: I M Ambros; J Benard; M Boavida; N Bown; H Caron; V Combaret; J Couturier; C Darnfors; O Delattre; J Freeman-Edward; C Gambini; N Gross; C M Hattinger; A Luegmayr; J Lunec; T Martinsson; K Mazzocco; S Navarro; R Noguera; S O'Neill; U Potschger; S Rumpler; F Speleman; G P Tonini; A Valent; N Van Roy; G Amann; B De Bernardi; P Kogner; R Ladenstein; J Michon; A D J Pearson; P F Ambros Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544